$2.34T
Total marketcap
$86.95B
Total volume
BTC 50.00%     ETH 15.41%
Dominance

Bio-Techne Corporation TE1.F Stock

64 EUR {{ price }} 0.000000% {{change_pct}}%
COUNTRY
Germany
Exchange
Frankfurt
Market Cap
10.06B EUR
LOW - HIGH [24H]
64 - 64 EUR
VOLUME [24H]
2 EUR
{{ volume }}
P/E Ratio
49.61
Earnings per share
1.29 EUR

Bio-Techne Corporation Price Chart

Bio-Techne Corporation TE1.F Financial and Trading Overview

Bio-Techne Corporation stock price 64 EUR
Previous Close 69.5 EUR
Open 69.5 EUR
Bid 69 EUR x N/A
Ask 77 EUR x N/A
Day's Range 69.5 - 69.5 EUR
52 Week Range 65.5 - 94.5 EUR
Volume 60 EUR
Avg. Volume 0 EUR
Market Cap 11.08B EUR
Beta (5Y Monthly) 1.256338
PE Ratio (TTM) 46.02649
EPS (TTM) 1.29 EUR
Forward Dividend & Yield 0.3 (0.41%)
Ex-Dividend Date May 12, 2023
1y Target Est 549.6 EUR

TE1.F Valuation Measures

Enterprise Value 11.1B EUR
Trailing P/E 46.02649
Forward P/E 7.713651
PEG Ratio (5 yr expected) 4.22
Price/Sales (ttm) 9.865498
Price/Book (mrq) 5.7868443
Enterprise Value/Revenue 9.88
Enterprise Value/EBITDA 32.244

Trading Information

Bio-Techne Corporation Stock Price History

Beta (5Y Monthly) 1.256338
52-Week Change -9.86%
S&P500 52-Week Change 20.43%
52 Week High 94.5 EUR
52 Week Low 65.5 EUR
50-Day Moving Average 73.5 EUR
200-Day Moving Average 74.55 EUR

TE1.F Share Statistics

Avg. Volume (3 month) 0 EUR
Avg. Daily Volume (10-Days) 0 EUR
Shares Outstanding 157.44M
Float 155.97M
Short Ratio N/A
% Held by Insiders 0.89%
% Held by Institutions 96.50%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0.32
Trailing Annual Dividend Yield 0.46%
5 Year Average Dividend Yield 49.00%
Payout Ratio 0.1908
Last Split Factor 4:1

Financial Highlights

Fiscal Year

Fiscal Year Ends June 30, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End June 30, 2023

Profitability

Profit Margin 24.14%
Operating Margin (ttm) 24.80%
Gross Margin 68.16%
EBITDA Margin 30.64%

Management Effectiveness

Return on Assets (ttm) 7.11%
Return on Equity (ttm) 15.09%

Income Statement

Revenue (ttm) 1.12B EUR
Revenue Per Share (ttm) 7.16 EUR
Quarterly Revenue Growth (yoy) 1.30%
Gross Profit (ttm) 758.09M EUR
EBITDA 344.29M EUR
Net Income Avi to Common (ttm) 271.22M EUR
Diluted EPS (ttm) 1.51
Quarterly Earnings Growth (yoy) 15.59%

Balance Sheet

Total Cash (mrq) 157.2M EUR
Total Cash Per Share (mrq) 1 EUR
Total Debt (mrq) 473.99M EUR
Total Debt/Equity (mrq) 25.08 EUR
Current Ratio (mrq) 4.045
Book Value Per Share (mrq) 12.01

Cash Flow Statement

Operating Cash Flow (ttm) 273.72M EUR
Levered Free Cash Flow (ttm) 225.2M EUR

Profile of Bio-Techne Corporation

Country Germany
State MN
City Minneapolis
Address 614 McKinley Place N.E.
ZIP 55413
Phone 612 379 8854
Website https://www.bio-techne.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 3000

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It has strategic partnership with Lunaphore Technologies S.A. to develop automated same-slide spatial multiomics solution. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Q&A For Bio-Techne Corporation Stock

What is a current TE1.F stock price?

Bio-Techne Corporation TE1.F stock price today per share is 64 EUR.

How to purchase Bio-Techne Corporation stock?

You can buy TE1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Bio-Techne Corporation?

The stock symbol or ticker of Bio-Techne Corporation is TE1.F.

Which industry does the Bio-Techne Corporation company belong to?

The Bio-Techne Corporation industry is Biotechnology.

How many shares does Bio-Techne Corporation have in circulation?

The max supply of Bio-Techne Corporation shares is 157.19M.

What is Bio-Techne Corporation Price to Earnings Ratio (PE Ratio)?

Bio-Techne Corporation PE Ratio is 49.61240400 now.

What was Bio-Techne Corporation earnings per share over the trailing 12 months (TTM)?

Bio-Techne Corporation EPS is 1.29 EUR over the trailing 12 months.

Which sector does the Bio-Techne Corporation company belong to?

The Bio-Techne Corporation sector is Healthcare.